Table 1.
Targets/pathways of SNHG12 in different tissues/cell lines in various cancers.
| Cancer | Tissues/cell lines studied | Approx. mean fold up-regulation compared to control samples | Genes/proteins/pathways affected | Validation methods | Useful for prognosis, diagnosis, and therapeutics | References |
|---|---|---|---|---|---|---|
| Gastric cancer | Tissues, SGC-7901, AGS | 1.5-fold 2.5-fold 2.7-fold | ↓miR-320, ↑CRKL, ↑p-Akt, ↑p-Erk | qRT-PCR, immunoblot | Yes | (10, 36) |
| Tissues, SGC-7901, BGC-823 | 1.6-fold 13-fold 15-fold | ↓ miR-199a/b-5p | qRT-PCR | |||
| Non-small cell lung cancer | H1299, A549 | 2.7-fold 2.2-fold | ↓miR-138 | qRT-PCR | Yes | (25, 31, 32, 37–39) |
| Tissues, H1299, A549, PC9, A549/DDP, A549/PTX, PC9/AB2 | 2.3-fold 2.3-fold 3-fold 2.5-fold 5-fold 4.8-fold 5.5-fold | ↓miR-181a, ↑MAPK1, ↑MAP2K1, ↑Slug, ↑MAPK/Slug pathway | qRT-PCR, immunoblot | |||
| Tissues | 27-fold | qRT-PCR | ||||
| Tissues | 1.25-fold | ↓miR-218, ↑MMP9, ↑Vimentin, ↑Slug, ↑ZEB2, ↓E-Cadherin | qRT-PCR, immunoblot | |||
| Triple-negative breast cancer | Tissues, MDA-MB-231 BT-549 | 2.2-fold Not determined | ↑MMP13 | qRT-PCR | Yes | (9) |
| Hepato-cellular carcinoma | Tissues, SK-Hep1 HCCLM9 | 3.7-fold Not determined | ↓miR-199a/b-5p, ↑MLK3, ↑ IκB, ↑NF-κB | qRT-PCR, ChIRP assay, immunoblot | Yes | (8, 40) |
| Colorectal cancer | Tissues, SW480, HT29 | 2.5-fold 2-fold 4.7-fold | ↑Akt, ↑PI3K/AKT signaling pathway, ↑CDK4, ↑ CDK6, ↑CCND1, ↓Caspase-3 | qRT-PCR, immunoblot | Yes | (30) |
| Bladder cancer | Tissues, UMUC3, SW780 | 1.1-fold Not determined | ↑HDAC10, ↑AGER, ↓PCDH7, ↓LATS2 | qRT-PCR, microarray | Yes | (28) |
| Papillary thyroid cancer | Tissues, BCPAP, TPC1, K1 | 3.8-fold 6-fold 5-fold 3-fold | ↑Wnt/β-catenin signaling pathway, ↑β-catenin, ↑MMP-2, ↑cyclin D1 | qRT-PCR, immunoblot | Yes | (27) |
| Glioma | Tissues, U251, U87 | 3.3-fold 5.3-fold 5.2-fold | ↓miR-101-3p, ↑FOXP1 | qRT-PCR, immunoblot | s | (12, 26, 41) |
| Tissues, U251, U87 | 2.2-fold 4.2-fold 3.8-fold | ↑HuR | qRT-PCR, immunoblot | |||
| Tissues, U251, U87 | 5.5-fold 13-fold 11-fold | ↑TDP4, ↓miR-195, ↑SOX5, ↑Gelsolin | qRT-PCR, immunoblot | |||
| Cervical cancer | Tissues, CaSki, SiHa | 1.8-fold 6.3-fold 5.3-fold | ↓miR-424-5p | qRT-PCR, immunoblot | (33, 34, 42–44) | |
| HeLa, SiHa | 3.5-fold 3.3-fold | ↓miR-125b, ↑STAT3 | qRT-PCR | |||
| Nasopharyngeal cancer | Tissues, CNE1, SUNE1 | 1.5-fold 10-fold 7.7-fold | ↑Notch pathway | qRT-PCR | Yes | (35) |
| Osteosarcoma | Tissues, MG-63 | 3.4-fold 3.3-fold | ↑Angiomotin | qRT-PCR | Yes | (11, 29, 45, 46) |
| Tissues, 143B, U2OS | 2.9-fold 6.2-fold 5.6-fold | ↓miR-195-5p, ↑CDK4, ↑CDK6, ↑CCND1, ↑Notch, ↑Notch signaling | qRT-PCR | |||
| DXR resistant tissues, MG-63, U2OS, MG-63/DXR | 2.5-fold 3.9-fold 3.8-fold 5.4-fold | ↓miR-320a, ↑MCL1 | qRT-PCR | |||
| Prostate cancer | Tissues LNCaP PC-3 C4-2 | 1.8-fold 22-fold 14-fold 11-fold | ↓miR-133b, ↑P53 signaling pathway | qRT-PCR | Yes | (47, 48) |
| Tissues PC-3 DU145 | 1.8-fold 1.7-fold 2.3-fold | ↓miR-195, ↑β-catenin, ↑Cyclin D1, ↑ c-Myc, ↑Wnt/ β-catenin signaling | qRT-PCR | |||
| Renal cell carcinoma | Tissues Caki-1 ACHN | 1.75-fold 5.6-fold 5.8-fold | ↓miR-199a-5p, ↓PARP, ↓Caspase-3, ↑HIF1α | qRT-PCR | Yes | (49) |
| Ovarian Cancer | Tissues A2780 HO8910 | 1.7-fold 1.5-fold 3-fold | ↓miR-129, ↑SOX4 | qRT-PCR | Yes | (50) |
| Natural killer/T-cell lymphoma | Tissues SNK-6 YTS | 1.29-fold 4.6-fold 3-fold | ↑c-Myc, ↑P-gp | qRT-PCR | Yes | (51) |